Neuromielitis óptica: estado del arte / Neuromyelitis optica: sState of the art
Salud UNINORTE
; 23(2): 204-219, dic. 2007. ilus, tab
Artigo
em Espanhol
| LILACS
| ID: lil-480347
Biblioteca responsável:
CO5.1
ABSTRACT
Neuromyelitis optica is an idiopathic, severe, demyelinating disease of the central nervous system predominantly affecting optic nerves and spinal cord. Clinical, radiologic, and immunologic features distinguish neuromyelitis optica from other severe cases of multiple sclerosis. A serum immunoglobulin G autoantibody (NMO-IgG) serves as a specific markerfor Neuromyelitis optica. NMO-IgG is the first specific marker for a central nervous system demyelinating disease. The molecular target of NMO-IgG was identified as aquaporin-4 water channel, is the most abundant water channel in the brain and is concentrated in theastrocyte membranes that border. NMO-IgG seropositivity is now incorporated into new diagnostic criteria for neuromyelitis optica. Clinical onset and course is 8090 percent relapsing course, 1020 percent monophasic course. Intravenous corticosteroid therapy is commonly the initial treatment for acute attacks of optic neuritis or myelitis. Therapeutic plasmapheresis is an effective rescue treatment for steroid unresponsive NMO attacks. Immunossupressive agents are used for relapse prevention. Immunosuppressive treatment is indicated in patients with a diagnosis of relapsing neuromyelitis optica.
Texto completo:
Disponível
Coleções:
Bases de dados internacionais
Base de dados:
LILACS
Assunto principal:
Neurite Óptica
/
Neuromielite Óptica
/
Esclerose Múltipla
/
Mielite Transversa
Tipo de estudo:
Estudo prognóstico
Limite:
Humanos
Idioma:
Espanhol
Revista:
Salud UNINORTE
Assunto da revista:
Saúde Pública
Ano de publicação:
2007
Tipo de documento:
Artigo
País de afiliação:
Colômbia
Instituição/País de afiliação:
Universidad Libre/CO